Stock Track | Catalyst Pharmaceuticals Soars 6.36% After-Hours on Strong Q3 Results, Raised Guidance, and Share Buyback

Stock Track11-06

Catalyst Pharmaceuticals (CPRX) saw its stock surge 6.36% in after-hours trading on Wednesday, following the release of its impressive third-quarter 2025 financial results. The biopharmaceutical company not only beat revenue estimates but also raised its full-year guidance and announced a significant share repurchase program, signaling strong confidence in its future prospects.

The company reported Q3 revenue of $148.40 million, surpassing analyst expectations of $136.80 million. This represents a robust 17.4% year-over-year growth, primarily driven by the strong performance of its flagship product, FIRDAPSE, and the successful uptake of AGAMREE. Catalyst's adjusted net income for the quarter stood at $86.10 million, while operating income reached $66.30 million.

In light of these strong results, Catalyst Pharmaceuticals raised its full-year 2025 revenue guidance to $565-$585 million, up from previous estimates. The company also increased its 2025 AGAMREE revenue guidance to $105-$115 million, while maintaining its FIRDAPSE revenue guidance at $355-$360 million. Furthermore, in a move that underscores management's confidence in the company's outlook, Catalyst announced a $200 million share repurchase program. These positive developments, coupled with sustained organic growth and market penetration of its key products, have likely contributed to the stock's after-hours rally.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1150592811?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 06:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1150592811","market":"us","top_or_hot":-1,"title":"Stock Track | Catalyst Pharmaceuticals Soars 6.36% After-Hours on Strong Q3 Results, Raised Guidance, and Share Buyback","media":"Stock Track","content":"<p>Catalyst Pharmaceuticals (CPRX) saw its stock surge 6.36% in after-hours trading on Wednesday, following the release of its impressive third-quarter 2025 financial results. The biopharmaceutical company not only beat revenue estimates but also raised its full-year guidance and announced a significant share repurchase program, signaling strong confidence in its future prospects.</p>\n\n<p>The company reported Q3 revenue of $148.40 million, surpassing analyst expectations of $136.80 million. This represents a robust 17.4% year-over-year growth, primarily driven by the strong performance of its flagship product, FIRDAPSE, and the successful uptake of AGAMREE. Catalyst's adjusted net income for the quarter stood at $86.10 million, while operating income reached $66.30 million.</p>\n\n<p>In light of these strong results, Catalyst Pharmaceuticals raised its full-year 2025 revenue guidance to $565-$585 million, up from previous estimates. The company also increased its 2025 AGAMREE revenue guidance to $105-$115 million, while maintaining its FIRDAPSE revenue guidance at $355-$360 million. Furthermore, in a move that underscores management's confidence in the company's outlook, Catalyst announced a $200 million share repurchase program. These positive developments, coupled with sustained organic growth and market penetration of its key products, have likely contributed to the stock's after-hours rally.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Catalyst Pharmaceuticals Soars 6.36% After-Hours on Strong Q3 Results, Raised Guidance, and Share Buyback</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Catalyst Pharmaceuticals Soars 6.36% After-Hours on Strong Q3 Results, Raised Guidance, and Share Buyback\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-06 06:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Catalyst Pharmaceuticals (CPRX) saw its stock surge 6.36% in after-hours trading on Wednesday, following the release of its impressive third-quarter 2025 financial results. The biopharmaceutical company not only beat revenue estimates but also raised its full-year guidance and announced a significant share repurchase program, signaling strong confidence in its future prospects.</p>\n\n<p>The company reported Q3 revenue of $148.40 million, surpassing analyst expectations of $136.80 million. This represents a robust 17.4% year-over-year growth, primarily driven by the strong performance of its flagship product, FIRDAPSE, and the successful uptake of AGAMREE. Catalyst's adjusted net income for the quarter stood at $86.10 million, while operating income reached $66.30 million.</p>\n\n<p>In light of these strong results, Catalyst Pharmaceuticals raised its full-year 2025 revenue guidance to $565-$585 million, up from previous estimates. The company also increased its 2025 AGAMREE revenue guidance to $105-$115 million, while maintaining its FIRDAPSE revenue guidance at $355-$360 million. Furthermore, in a move that underscores management's confidence in the company's outlook, Catalyst announced a $200 million share repurchase program. These positive developments, coupled with sustained organic growth and market penetration of its key products, have likely contributed to the stock's after-hours rally.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CPRX","symbol_name":"Catalyst Pharmaceutical Partners","start_time":0,"source_url":"","article_id":"1150592811","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1150592811","pubTimestamp":1762380550,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Catalyst Pharmaceuticals (CPRX) saw its stock surge 6.36% in after-hours trading on Wednesday, following the release of its impressive third-quarter 2025 financial results. The biopharmaceutical...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CPRX":"Catalyst Pharmaceutical Partners"},"translate_title":"个股赛道|Catalyst Pharmaceuticals盘后飙升6.36%，得益于强劲的Q3业绩、上调指引和股票回购","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CPRX":1},"content_text":"Catalyst Pharmaceuticals (CPRX) saw its stock surge 6.36% in after-hours trading on Wednesday, following the release of its impressive third-quarter 2025 financial results. The biopharmaceutical company not only beat revenue estimates but also raised its full-year guidance and announced a significant share repurchase program, signaling strong confidence in its future prospects.\nThe company reported Q3 revenue of $148.40 million, surpassing analyst expectations of $136.80 million. This represents a robust 17.4% year-over-year growth, primarily driven by the strong performance of its flagship product, FIRDAPSE, and the successful uptake of AGAMREE. Catalyst's adjusted net income for the quarter stood at $86.10 million, while operating income reached $66.30 million.\nIn light of these strong results, Catalyst Pharmaceuticals raised its full-year 2025 revenue guidance to $565-$585 million, up from previous estimates. The company also increased its 2025 AGAMREE revenue guidance to $105-$115 million, while maintaining its FIRDAPSE revenue guidance at $355-$360 million. Furthermore, in a move that underscores management's confidence in the company's outlook, Catalyst announced a $200 million share repurchase program. These positive developments, coupled with sustained organic growth and market penetration of its key products, have likely contributed to the stock's after-hours rally.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1150592811","isCrawlerRequest":true}